Applied Therapeutics (NASDAQ:APLT) Issues Earnings Results

Applied Therapeutics (NASDAQ:APLTGet Rating) posted its earnings results on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.05), MarketWatch Earnings reports.

NASDAQ APLT traded down $0.04 during trading hours on Friday, hitting $1.72. 132,889 shares of the company traded hands, compared to its average volume of 173,958. The business’s 50-day moving average is $2.00 and its 200-day moving average is $5.44. Applied Therapeutics has a twelve month low of $1.45 and a twelve month high of $25.59.

In related news, insider Riccardo Perfetti purchased 30,000 shares of Applied Therapeutics stock in a transaction that occurred on Wednesday, March 23rd. The stock was purchased at an average cost of $1.97 per share, with a total value of $59,100.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 27.20% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its stake in shares of Applied Therapeutics by 1,503.4% during the first quarter. Renaissance Technologies LLC now owns 282,200 shares of the company’s stock worth $595,000 after purchasing an additional 264,600 shares during the period. BlackRock Inc. increased its stake in shares of Applied Therapeutics by 5.0% during the first quarter. BlackRock Inc. now owns 1,363,403 shares of the company’s stock worth $2,876,000 after purchasing an additional 64,872 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Applied Therapeutics by 220.4% during the third quarter. Dimensional Fund Advisors LP now owns 50,184 shares of the company’s stock worth $832,000 after purchasing an additional 34,521 shares during the period. Acadian Asset Management LLC bought a new position in shares of Applied Therapeutics during the first quarter worth approximately $70,000. Finally, State Street Corp increased its stake in shares of Applied Therapeutics by 8.8% during the fourth quarter. State Street Corp now owns 341,651 shares of the company’s stock worth $3,058,000 after purchasing an additional 27,700 shares during the period. Hedge funds and other institutional investors own 95.51% of the company’s stock.

Several research analysts have recently weighed in on the company. Zacks Investment Research raised Applied Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Wednesday, March 2nd. Barclays reduced their price objective on Applied Therapeutics from $7.00 to $2.50 and set an “equal weight” rating for the company in a research report on Monday, March 21st. Finally, Truist Financial reduced their price objective on Applied Therapeutics to $6.00 in a research report on Wednesday, April 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $12.08.

Applied Therapeutics Company Profile (Get Rating)

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.

Featured Stories

Earnings History for Applied Therapeutics (NASDAQ:APLT)

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.